

# Susanne Neumann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4855097/publications.pdf>

Version: 2024-02-01

42  
papers

1,325  
citations

394421

19  
h-index

361022

35  
g-index

42  
all docs

42  
docs citations

42  
times ranked

737  
citing authors

#	ARTICLE	IF	CITATIONS
1	TSH stimulation of human thyroglobulin and thyroid peroxidase gene transcription is partially dependent on internalization. <i>Cellular Signalling</i> , 2022, 90, 110212.	3.6	1
2	Graves'™ Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays. <i>Thyroid</i> , 2021, , .	4.5	2
3	Inhibition of TSH/IGF-1 receptor crosstalk by Teprotumumab as a treatment modality of Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, , .	3.6	9
4	Thyrotropin, but Not Thyroid-Stimulating Antibodies, Induces Biphasic Regulation of Gene Expression in Human Thyrocytes. <i>Thyroid</i> , 2020, 30, 270-276.	4.5	12
5	Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by G <sub>s</sub> and G <sub>i/o</sub> Proteins. <i>Molecular Pharmacology</i> , 2020, 97, 2-8.	2.3	10
6	Is There Evidence for IGF1R-Stimulating Abs in Graves'™ Orbitopathy Pathogenesis?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6561.	4.1	10
7	The intramolecular agonist is obligate for activation of glycoprotein hormone receptors. <i>FASEB Journal</i> , 2020, 34, 11243-11256.	0.5	15
8	TSH Elicits Cell-Autonomous, Biphasic Responses: A Mechanism Inhibiting Hyperstimulation. <i>Endocrinology</i> , 2020, 161, .	2.8	2
9	Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease. <i>European Thyroid Journal</i> , 2020, 9, 59-65.	2.4	17
10	Thyrotropin regulation of differentiated gene transcription in adult human thyrocytes in primary culture. <i>Molecular and Cellular Endocrinology</i> , 2020, 518, 111032.	3.2	12
11	TSH Receptor Homodimerization in Regulation of cAMP Production in Human Thyrocytes in vitro. <i>Frontiers in Endocrinology</i> , 2020, 11, 276.	3.5	12
12	β-Arrestin 1 in Thyrotropin Receptor Signaling in Bone: Studies in Osteoblast-Like Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 312.	3.5	7
13	TSH/IGF1 receptor crosstalk: Mechanism and clinical implications. , 2020, 209, 107502.		35
14	Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk. <i>Endocrinology</i> , 2019, 160, 1468-1479.	2.8	38
15	Letter to the Editor: 'Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy', <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1075-1076.	3.6	1
16	Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors. <i>Thyroid</i> , 2018, 28, 650-655.	4.5	26
17	Thyroid stimulating hormone (TSH)/insulin-like growth factor 1 (IGF1) receptor cross-talk in Human cells. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 2, 29-33.	1.4	15
18	Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 38-45.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Normal Human Thyrocytes in Culture. <i>Methods in Molecular Biology</i> , 2018, 1817, 1-7.	0.9	8
20	TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis. <i>Thyroid</i> , 2017, 27, 746-747.	4.5	29
21	Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 2017, 174, 328-340.	5.4	26
22	De novo triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone. <i>Journal of Biological Chemistry</i> , 2017, 292, 15434-15444.	3.4	27
23	Rebuttal to Smith and Janssen ( <i>Thyroid</i> 2017;27:746-747. DOI: 10.1089/thy.2017.0281). <i>Thyroid</i> , 2017, 27, 1459-1460.	4.5	4
24	An Enantiomer of an Oral Small-Molecule TSH Receptor Agonist Exhibits Improved Pharmacologic Properties. <i>Frontiers in Endocrinology</i> , 2016, 7, 105.	3.5	18
25	Thyrotropin Stimulates Differentiation Not Proliferation of Normal Human Thyrocytes in Culture. <i>Frontiers in Endocrinology</i> , 2016, 7, 168.	3.5	17
26	TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2340-2347.	3.6	104
27	Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium/Iodide Symporter Expression in Primary Cultures of Human Thyrocytes. <i>Thyroid</i> , 2016, 26, 1794-1803.	4.5	43
28	Multiple Transduction Pathways Mediate Thyrotropin Receptor Signaling in Preosteoblast-Like Cells. <i>Endocrinology</i> , 2016, 157, 2173-2181.	2.8	15
29	Bidirectional TSH and IGF-1 Receptor Cross Talk Mediates Stimulation of Hyaluronan Secretion by Graves' Disease Immunoglobulins. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1071-1077.	3.6	91
30	A Selective TSH Receptor Antagonist Inhibits Stimulation of Thyroid Function in Female Mice. <i>Endocrinology</i> , 2014, 155, 310-314.	2.8	88
31	Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation. <i>FASEB Journal</i> , 2014, 28, 3446-3455.	0.5	55
32	A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp. <i>PLoS ONE</i> , 2014, 9, e90766.	2.5	16
33	A Drug-Like Antagonist Inhibits Thyrotropin Receptor-Mediated Stimulation of cAMP Production in Graves' Orbital Fibroblasts. <i>Thyroid</i> , 2012, 22, 839-843.	4.5	61
34	A New Small-Molecule Antagonist Inhibits Graves' Disease Antibody Activation of the TSH Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 548-554.	3.6	90
35	Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling. <i>FASEB Journal</i> , 2011, 25, 3687-3694.	0.5	55
36	Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on internalization. <i>FASEB Journal</i> , 2010, 24, 3992-3999.	0.5	25

#	ARTICLE	IF	CITATIONS
37	Constitutively Active Thyrotropin and Thyrotropin-Releasing Hormone Receptors and Their Inverse Agonists. <i>Methods in Enzymology</i> , 2010, 485, 147-160.	1.0	16
38	A Small Molecule Inverse Agonist for the Human Thyroid-Stimulating Hormone Receptor. <i>Endocrinology</i> , 2010, 151, 3454-3459.	2.8	54
39	Human TSH receptor ligands as pharmacological probes with potential clinical application. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 669-679.	2.4	19
40	Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12471-12476.	7.1	102
41	A Low-Molecular-Weight Antagonist for the Human Thyrotropin Receptor with Therapeutic Potential for Hyperthyroidism. <i>Endocrinology</i> , 2008, 149, 5945-5950.	2.8	90
42	Low Affinity Analogs of Thyrotropin-releasing Hormone Are Super-agonists. <i>Journal of Biological Chemistry</i> , 2006, 281, 13103-13109.	3.4	34